BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DNL628 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of DNL628\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07328451-695@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:DNL628: Phase 1 readout est. (NCT07328451)
DESCRIPTION:DNL628\, phase 1\, Alzheimer's Disease.\nStudy: A Study to Eval
 uate the Safety\, Tolerability\, Pharmacokinetics\, and Pharmacodynamics o
 f DNL628 in Participants With Early Alzheimer's Disease\nEstimated primary
  completion: February 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/dnl628#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07328451
URL:https://assetmemo.bio/drug/dnl628#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
